Skip to content

Effect of microfragments of autologous adipose tissue on wound healing in patients with diabetic foot ulcers foot ulcers

Effect of microfragments of autologous adipose tissue on wound healing in patients with diabetic foot ulcers foot ulcers

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500102518
Enrollment
Unknown
Registered
2025-05-15
Start date
2025-05-25
Completion date
Unknown
Last updated
2025-05-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetes

Interventions

Conventional treatment cohort:Standard treatment
Autologous fat microfragment transplantation treatment group:Autologous fat microfragment transplantation

Sponsors

The First Affiliated Hospital of Wenzhou Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Age >= 18 years but = 1 cm^2 (after debridement, aim to remove necrotic, dead, and fibrous tissue as much as possible). If the patient has multiple lesions, one lesion must be selected as the qualifying lesion for certification and subsequent evaluation; 5. Standard treatment for diabetic foot ulcers with a wound area reduction of <= 20% in one week.

Exclusion criteria

Exclusion criteria: 1. Patients had a significant history of acute cardiovascular and cerebrovascular disease, such as acute myocardial infarction, severe angina pectoris, acute stroke, or transient ischemic attack, within 3 months before the study began; 2. Have severe uncontrolled hypertension, systolic blood pressure >= 180 mmHg or diastolic blood pressure >=110 mmHg at screening; 3. Patients with severe renal insufficiency (creatinine > 200µmol/L or creatinine clearance < 30 ml/min); 4. All types of diabetic coma; 5. Have had malignant tumors or suspected malignant tumors (general physical examination, abdominal ultrasound examination, chest X-ray, blood chemistry examination, etc.); 6. Patients with benign tumors at ulcer sites; 7. The patient has an immunocompromised disease, such as HIV. Use of drugs that can interfere with assessment: such as corticosteroids and immunosuppressants; 8. Pregnant women or lactating women, or male or female patients who plan to become pregnant during the study period and do not want to take contraceptive measures during treatment; 9. Patients whose health condition does not permit liposuction under local anesthesia; 10. Patients judged by the investigator to be unsuitable for clinical trials.

Design outcomes

Primary

MeasureTime frame
Skin healing rate;

Secondary

MeasureTime frame
Time required for granulation formation >75%;Time required for complete skin healing;Rate of amputation and recurrence;Assessment of foot function;

Countries

China

Contacts

Public ContactJing Hong

The First Affiliated Hospital of Wenzhou Medical Universit

hongjing@wmu.edu.cn+86 138 5889 2882

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026